Walleye Trading
ALXN

Walleye Trading’s Alexion Pharmaceuticals ALXN Stock Holding History

Walleye Trading’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,742
Closed -$3.44M – 6111
2021
Q2 		$3.44M Buy
18,742
+12,998
+226% +$2.23M 0.01% 1056
2021
Q1 		$878K Sell
5,744
-7,993
-58% -$1.24M ﹤0.01% 2044
2020
Q4 		$2.15M Sell
13,737
-23,915
-64% -$3.07M 0.01% 1341
2020
Q3 		$4.31M Sell
37,652
-5,155
-12% -$556K 0.02% 649
2020
Q2 		$4.8M Sell
42,807
-16,958
-28% -$1.8M 0.03% 553
2020
Q1 		$5.37M Buy
59,765
+14,935
+33% +$1.47M 0.04% 361
2019
Q4 		$4.85M Buy
44,830
+4,236
+10% +$453K 0.03% 597
2019
Q3 		$3.98M Buy
40,594
+26,697
+192% +$3.01M 0.03% 590
2019
Q2 		$1.82M Buy
13,897
+11,225
+420% +$1.45M 0.02% 1117
2019
Q1 		$361K Sell
2,672
-38,451
-94% -$4.78M ﹤0.01% 2533
2018
Q4 		$4M Buy
41,123
+25,725
+167% +$3.04M 0.03% 603
2018
Q3 		$2.14M Sell
15,398
-2,501
-14% -$314K 0.01% 1262
2018
Q2 		$2.22M Sell
17,899
-4,594
-20% -$537K 0.01% 1238
2018
Q1 		$2.51M Sell
22,493
-9,049
-29% -$1.08M 0.01% 1008
2017
Q4 		$3.77M Buy
+31,542
New +$3.84M 0.02% 835
2017
Q3 		– Sell
-22,031
Closed -$2.99M – 4779
2017
Q2 		$2.68M Buy
22,031
+14,103
+178% +$1.64M 0.02% 985
2017
Q1 		$961K Buy
7,928
+1,583
+25% +$204K 0.01% 1681
2016
Q4 		$776K Buy
+6,345
New +$776K 0.01% 1730
2016
Q3 		– Sell
-453
Closed -$58.3K – 5636
2016
Q2 		$53K Buy
+453
New +$64.3K ﹤0.01% 3938
2015
Q4 		– Sell
-12,213
Closed -$2.13M – 5873
2015
Q3 		$1.91M Buy
12,213
+2,937
+32% +$536K 0.02% 685
2015
Q2 		$1.68M Buy
9,276
+5,591
+152% +$965K 0.02% 809
2015
Q1 		$639K Buy
+3,685
New +$667K 0.01% 1314
2014
Q1 		– Sell
-8,500
Closed -$1.13M – 4044
2013
Q4 		$1.13M Buy
8,500
+7,437
+700% +$892K 0.01% 1021
2013
Q3 		$123K Buy
+1,063
New +$117K ﹤0.01% 1898

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Walleye Trading's ALXN Position: Q3 2021 in Review

Walleye Trading sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 18,742 shares — an estimated $3.44M sold.

Walleye Trading first reported a position in ALXN in Q3 2013 and held it in 24 quarters. The position peaked at $5.37M in Q1 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Walleye Trading reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Walleye Trading sold 18,742 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.44M.
  • Walleye Trading first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 24 quarters.
  • Walleye Trading's Alexion Pharmaceuticals position peaked at $5.37M in Q1 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Walleye Trading's 13F filing for Q3 2021, filed 15 Nov 2021.